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A B S T R A C T
CD8 regulatory T cells (Treg) and CD4CD25 Treg inﬁltrate human cancers, thus favoring tumor immune
escape. Therefore, in the setting of antitumor therapeutic protocols, it is important to associate antitumor
treatment with agents that are able to inhibit Treg function. Cyclophosphamide (CY) has been demonstrated
to be effective in counteracting CD4CD25 Treg activity. Hence, we tested its inhibitory efﬁcacy on human
CD8 Treg. Because CY is a prodrug, 4-hydroperoxycyclophosphamide (4-HC), a derivative of CY that in
aqueous solution is converted to 4-hydroxycyclophosphamide, an active metabolite of CY, was used. 4-HC
signiﬁcantly inhibited CD8 Treg generation and function but only at the higher tested concentration (0.5
g/mL), that is, in the therapeutic range of the drug. The lower 4-HC concentration tested (0.1 g/mL) was
almost ineffective. 4-HC inhibitory effects were related to apoptosis/necrosis induction. When CD8CD28
non-Tregwere analyzed for comparative purposes, signiﬁcantly lower cytotoxic rates among these cellswere
observed than among CD8 Treg, whichwere differentiated because they did not express the CD28molecule.
These data demonstrate that CD8 Treg are inhibited through cytotoxic phenomena by CY, thus supporting
the use of this drug at adequate concentrations and schedules of administration as a Treg inhibitor in
combinatorial chemo- or immunotherapeutic anticancer protocols.
 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rightsreserved.1. Introduction
Regulatory T cells (Treg) play a pivotal role in the maintenance
of immunologic self-tolerance, downregulating the activation/pro-
liferation of self-reactive T cells and thus preventing the develop-
ment of various autoimmune diseases [1,2]. However, Treg have
been detected among tumor-inﬁltrating lymphocytes [3,4]. Treg
inﬁltrating cancer lesions are thought to be responsible for the
inhibition of antitumor immune responses, thus favoring tumor
immune escape. Indeed, administration of ipilimumab [5], an agent
blocking the CTLA4-CD80/CD86 interaction—one of the molecular
circuits adopted by Treg for suppressing immune responses [6]—
as therapeutic effects against cancer [7]. The importance of coun-
eracting tumor-inﬁltrating Treg function to set antitumor proto-
ols of chemo- and/or immunotherapy that are more efﬁcient than
hose currently in use is therefore clear. However, Treg belong to
ifferent T cell lineages [8,9] and each Treg subtype uses different
echanisms to induce immune suppression [10,11]. Hence, the
search for additional agents that can block tumor-inﬁltrating Treg* Corresponding author.
E-mail address: gﬁlaci@unige.it (G. Filaci).
0198-8859/$36.00  2012 American Society for Histocompatibility and Immunogenetics
doi:10.1016/j.humimm.2011.12.020ismandatory. The chemotherapeutic agent cyclophosphamide (CY)
has been reported to be effective on Treg. CY is a nitrogen mustard
alkylating agent that exhibits great cytotoxicity against cells ac-
tively replicating their DNA [12,13]. CY is an inactive prodrug that
requires activation by the hepatic cytochrome P-450 enzyme sys-
tem to form the active metabolite 4-hydroxycyclophosphamide,
which is in equilibriumwith its tautomer aldophosphamide. These
2 intermediate metabolites rapidly diffuse out of hepatic cells into
the circulation and are subsequently takenupbyother cells, includ-
ing cancer cells. Within the cells, aldophosphamide decomposes to
form the cytotoxic phosphoramide mustard, which produces the
interstrand DNA cross-links responsible for the cytotoxic proper-
ties of the drug. The selective toxicity on tumor cells occurs because
the concentration of the enzymes converting aldophosphamide
into the cytotoxicmetabolite is higher in tumor cells than in normal
cells [14]. CY is one of the most successful and widely used drugs for
the treatment of hematologic and solid malignancies [15,16], as well
as for the treatment of different autoimmune disorders [17], and
therefore is commonly considered an immunosuppressive drug.
However, evidence exists that CY may have immunostimulatory ef-
fects (i.e., enhancing the therapeutic activity of adoptive T cell immu-






































I. Traverso et al. / Human Immunology 73 (2012) 207-213208notherapy) [18]. Recent studies have linked the immunostimulating
effectofCY to the selective inhibition/depletionofCD4CD25Treg in
both experimental [19–21] andhuman [22,23] tumors. However, the
Treg repertoire also includes CD8 Treg; no information on
he sensitivity of CD8 Treg to CY is currently available. This article
eports data on the effects of 4-hydroperoxycyclophosphamide
4-HC), a derivative of CY that in aqueous solution is converted to
-hydroxycyclophosphamide (the active metabolite of CY) [24], on
D8 Treg function and viability.
. Subjects and methods
.1. Generation of CD8+ Treg from peripheral blood
CD8 Treg were generated as described previously [25]. Brieﬂy,
peripheral blood mononuclear cells (PBMC) were isolated from
buffy coats by centrifugation on a Ficoll–Hypaque gradient (Bio-
chrom AG, Berlin, Germany) for 30 minutes at 1800 rpm. PBMC
were incubated in RPMI 1640 culture medium (Gibco by Life Tech-
nologies Ltd., Paisley, UK) with 10% fetal calf serum (Invitrogen) in
culture ﬂasks (Corning Life Sciences, Amsterdam, The Netherlands)
at 37C overnight. CD8 T lymphocytes were puriﬁed from nonad-
erent cells by magnetic bead separation using microbeads conju-
atedwithmonoclonal antibody (mAb) speciﬁc for the CD8 antigen
Dynal CD8 positive isolation kit, Invitrogen by Life Technologies
td., Paisley, UK). Puriﬁed CD8 T lymphocytes (2 105 cells/well)
resuspended in culture medium consisting of RPMI 1640 (Gibco by
Life Technologies Ltd., Paisley, UK) with 10% fetal calf serum (Invit-
rogen by Life Technologies Ltd., Paisley, UK) were incubated with
20 U/mL of interleukin (IL)-2 (Proleukin, Eurocetus, Amsterdam,
The Netherlands) and 10 ng/mL of IL-10 (PeproTech) in 96-well
ﬂat-bottom plates (Corning Life Sciences, Amsterdam, The Nether-
lands) at 37C for 7 days.
Fig. 1. Analysis of 4-hydroperoxycyclophosphamide (4-HC) effects on CD8 regul
eripheral blood mononuclear cell (PBMC) proliferation (expressed as a percentage
f CD8 Treg generatedwith orwithout 4-HCused at 0.5 (A) or 0.1 (B)g/mL. (C) Rep
6 cultured in the presence or absence of CD8 Treg generated in the presence or absence
D) Comparison between the mean suppressive activity of untreated CD8 Treg and thatAt the end of the incubation, the cells were collected, washed,
ounted, and used as suppressors in a proliferation suppression
ssay.
.2. Proliferation suppression assay
The suppressive activity of Treg was evaluated by monitoring
he inhibition of dye dilution in PBMC stainedwith carboxyﬂuores-
ein succinimidyl ester (5 M;Molecular Probes, Invitrogen by Life
echnologies Ltd., Paisley, UK) before the test. Thereafter, the cells
ere pulsed with anti-CD3 UCHT1 mAb (5 g/mL, BD Bioscience,
ranklin Lakes, NJ) and cultured for 5 days in a 96-well round-
ottom plate (1 105 cells/well) in the presence (or absence) of in
itro–generated CD8 Treg (1  105 cells/well). At the end of the
ncubation the samples were washed in phosphate-buffered saline
nd analyzed using a FACSCanto ﬂow cytometer (BD Bioscience,
ranklin Lakes, NJ) using FACSDiva software (BD Biosciences,
ranklin Lakes, NJ).
.3. 4-HC treatment
4-HC was purchased from Niomech–IIT GmbH (University of
ielefeld, Bielefeld, Germany). The drugwas opportunely diluted to
e used at a ﬁnal concentration of 0.5 or 0.1 g/mL, concentrations
within the therapeutic range of 4-HC [26]. To evaluate the effects on
CD8 Treg generation, the drug was added to cultures during the
-day incubation with IL-2 and IL-10. To analyze 4-HC effects on
lready generated CD8 Treg, the drugwas added to cultures on the
th day of generation for 24 hours.
.4. Immunoﬂuorescence analyses
Cell expression of membrane antigens was analyzed by immu-
oﬂuorescence by incubating the cells (1  105 cells in 100 L of
T cell (Treg) generation. (A and B) Anti-CD3 monoclonal antibody (mAb)-induced
boxyﬂuorescein succinimidyl ester [CFSE]-diluted cells) in the presence or absence
ative results of proliferation analysis of anti-CD3mAb-stimulated PBMC fromdonoratory
of car
resentof either 0.5 or 0.1 g/mL of 4-HC. Percentages of proliferating cells are indicated.














I. Traverso et al. / Human Immunology 73 (2012) 207-213 209phosphate-buffered saline) with speciﬁc mAbs at 4C for 30 min-
utes in the dark. The following mAbs were used: ﬂuorescein iso-
thiocyanate (FITC)-conjugated anti-CD45RA, phycoerythrin (PE)-
conjugated anti-CD127, allophycocyanin-conjugated anti-CD39,
PE–cyanin 7–conjugated anti-CD8, and PerCP-conjugated anti-
CD28. After staining procedures, the cells were acquired and ana-
lyzed by a FACSCanto ﬂow cytometer using FACSDIVA software.
2.5. Analysis of apoptotic and necrotic cells
CD8puriﬁedT cells, preexposedor not to 4-HC,were incubated
with Pe–cyanin 7–conjugated anti-CD8 and allophycocyanin-
conjugated anti-CD28 for 15 minutes at room temperature in the
dark, following the manufacturer’s instructions. The percentage of
apoptotic cellswas assessed byﬂowcytometry after cell incubation
with FITC-conjugated annexin V (BD Pharmingen, San Diego, CA).
To quantify necrotic cells, 7-aminoactinomycin D (BD Biosciences,
Franklin Lakes, NJ) was added to the cells immediately before ﬂow
cytometric analysis. Cells stained only by FITC-conjugated annexin
V were considered apoptotic, whereas cells stained by both FITC-
conjugated annexin V and 7-aminoactinomycin D were enumer-
ated as necrotic cells.
2.6. Statistical analysis
All results are expressed as means standard deviation. Statis-
tically signiﬁcant differences between mean percentage data (re-
lated to apoptosis, necrosis, and suppressive activity of different T
cell subsets treated or not with 4-HC) were analyzed using the
Mann–Whitney test for nonparametric values. Correlations be-
tween variables were analyzed by Spearman’s correlation test. Dif-
ferences were considered signiﬁcant when p 0.05. The statistical
Fig. 2. Analysis of 4-hydroperoxycyclophosphamide (4-HC) effects on CD8 reg
mAb)-induced peripheral blood mononuclear cell (PBMC) proliferation (expresse
resence or absence of in vitro–generated CD8 Treg incubated for 24 hours with o
nalysis of anti-CD3mAb-stimulated PBMC from donor 16 cultured in the presence
g/mL of 4-HC. Percentages of proliferating cells are indicated. (D) Comparison between t
D8 Treg incubated for 24 hours with either 0.1 or 0.5 g/mL 4-HC.analyses were performed using GraphPad Prism 4.0 Software
(GraphPad Software Inc., San Diego, CA).
3. Results
3.1. Analysis of the effects of 4-HC on CD8+ Treg generation
and function
To evaluate the effects of 4-HC on in vitro generation of
CD8Treg, ex vivo puriﬁed CD8 T cells were incubated for 7 days
with the drug used at 0.1 or 0.5g/mL concentrations. The suppres-
ive activities of CD8Treg generated in the presence or absence of
he drugwere comparatively analyzed. Control CD8Treg exerted a
suppressive activity 25% in all analyzed samples. CD8Treg pre-
incubated with 0.5 g/mL of 4-HC exhibited signiﬁcantly lower
uppressive activity than control CD8Treg (12% vs 41%, p 
.0004; Fig. 1). To the contrary, the suppressive activity of
D8Treg pretreated with 4-HC at 0.1 g/mL concentration was
comparable to that of control CD8Treg (38% vs 41%, p  0.74;
Fig. 1).
To also assess the effects of 4-HC on the function of already
generated CD8Treg, in vitro–generated CD8Treg were incubated
for 24 hours with the drug used at the same concentrations as
above. Again, the suppressive activities of treated or untreated
CD8Treg treated were comparatively analyzed. CD8 Treg incu-
ated with 0.5 g/mL of 4-HC exhibited signiﬁcantly reduced sup-
pressive activity compared with control CD8Treg (20% vs 41% p
.0004; Fig. 2). Instead, the suppressive activity of CD8Treg incu-
ated overnight with 4-HC at 0.1 g/mL concentrationwas compa-
able to that of control CD8Treg (38% vs 41%, p  0.45; Fig. 2).
ry T cell (Treg) suppressive activity. (A and B) Anti-CD3 monoclonal antibody
percentage of carboxyﬂuorescein succinimidyl ester [CFSE]-diluted cells) in the
out 4-HC used at 0.5 (A) or 0.1 (B) g/L (C) Representative results of proliferation














































I. Traverso et al. / Human Immunology 73 (2012) 207-2132103.2. 4-HC does not alter the phenotype of CD8+ Treg
CD127, the IL-7 receptor, is downmodulated in Treg subpopula-
ions [27,28] so it is commonly monitored for assessing T cell
ifferentiation toward regulatory function. CD39 is a nucleosidase
ften expressed by Treg cells [29,30] and CD45RA is expressed on
on-antigen-speciﬁc CD8 Treg [9,31]. To assess whether the inhi-
bition of CD8 Treg suppressive activity was dependent on pheno-
typic changes eventually induced by 4-HC, the expression of CD127
(IL-7 R), CD39, and CD45RA antigenswas analyzed. Table 1 demon-
trates that 4-HC did not cause signiﬁcant variations of surface
ntigen expression when added to CD8 T cell cultures during
CD8 Treg generation. Comparable ﬁndingswere achievedwhen in
itro–generated CD8 Treg were incubated for 24 hours with 4-HC
(Table 2).
3.3. 4-HC induces CD8+ Treg apoptosis and necrosis
4-HC is an antiblastic drug; hence, its pharmacologic activity
ould be related to cell death induction. Therefore, the rates of
poptotic and necrotic cells in CD8 Treg exposed to 4-HC were
nalyzed. Because peripheral blood–derived CD8 Treg do not ex-
ress the CD28 antigen [25], the percentages of apoptotic and
ecrotic cells were calculated by gating CD8CD28 and CD8
CD28 T cells separately. Interestingly, the percentage of apoptotic
ells among CD8CD28 Treg generated in the presence of 0.5
g/mL of 4-HC was signiﬁcantly higher than that observed among
ntreated CD8CD28 Treg (Fig. 3A). Similarly, a signiﬁcantly
higher percentage of apoptotic cells was detected among in vitro–
generated CD8CD28 Treg incubated for 24 hours with 0.5 g/mL
of 4-HC comparedwith untreated CD8CD28 Treg (Fig. 3A). To the
contrary, comparable rates of apoptotic cells between treated and
untreated cells were observed when CD8CD28 Treg were incu-
atedwith 0.1g/mL of 4-HC either during or after Treg generation
Fig. 3A).
The analysis of necrosis in CD8CD28 Treg demonstrated a
signiﬁcantly increased percentage of necrotic cells among CD8
CD28 Treg generated in the presence of 4-HC, independent of drug
oncentration, compared with untreated CD8CD28 Treg (Fig.
3B). To the contrary, no signiﬁcant differences in necrotic cell per-
centage were detected between CD8CD28 Treg incubated or not
for 24 hours with 4-HC (Fig. 3B).
To achieve comparative information on sensitivity to 4-HC by
Treg (CD8CD28) and non-Treg (CD8CD28) T cell populations,
he percentages of apoptotic or necrotic cells were also analyzed
ithin the CD8CD28 T cells. CD8CD28 T cells incubated for 7
Table 1
Comparative analysis of antigen expression on basal CD8 T cells as well as on CD8







CD127 76a 16 46 19 39 11
D39 2 3 3 2 4 4
CD45RA 75 11 72 20 64 27
aData are expressed as percentages of positive cells.
Table 2
Comparative analysis of antigen expression on basal CD8 T cells as well as on CD8







CD127 76a 16 46 19 44 13
D39 2 3 3 2 3 2
D45RA 75 11 72 20 70 23aData are expressed as percentages of positive cells.days with 0.5 g/mL of 4-HC exhibited higher apoptosis percent-
ages compared with untreated cells (Fig. 3C). Similarly a signiﬁ-
cantly higher percentage of apoptotic cells was detected among
CD8CD28 T cells after their incubation for 24 hours with 0.5
g/mL of 4-HC compared with untreated cells. To the contrary,
omparable rates of apoptotic cells between treated and untreated
ellswere detectedwhen CD8CD28 T cellswere incubated for 24
ours or 7 days with 0.1 g/mL of 4-HC (Fig. 3C). Signiﬁcantly
ncreased percentages of necrotic T cells were only observed
mong CD8CD28 T cells incubated for 7 days with 0.1 or 0.5
g/mL of 4-HC, but not among CD8CD28 T cells incubated for 24
ours with 4-HC, comparedwith untreated cells (Fig. 3D). Interest-
ngly, the comparison of apoptotic cell percentages between
D8CD28 andCD8CD28Tcells subpopulations indicatedhigher
apoptotic rates in the former than in the latter T cell subpopulation
under all culture conditions (Fig. 4A). Similarly, comparison of ne-
crotic cell percentages between CD8CD28 and CD8CD28 T
cells indicated a higher level in the former than in the latter T cell
subpopulation under all culture conditions, with the exception of
cells incubated for 7 days with 0.5 g/mL of 4-HC (Fig. 4B).
To verify whether 4-HC-mediated inhibition of suppressive ac-
ivity could be strictly related to its cytotoxic effects on CD8 Treg,
he suppressive activity of CD8 Treg variably exposed to 4-HCwas
orrelated with drug-induced mortality (considering the sum of
ercentages of apoptotic and necrotic cells): Fig. 4C illustrates a
lear correlation between the 2 variables, thus supporting the con-
ept that the 4-HC impact on CD8 Treg activity ismainlymediated
y cytotoxic phenomena.
. Discussion
The results of this study indicate the following: (1) 4-HC, at a
ose of 0.5 g/mL, inhibits both CD8 Treg generation and func-
tion; and (2) 4-HC effects on CD8 Treg correlate with apoptosis/
necrosis induction.
Several previous studies have established that Treg cells are
crucial for maintaining peripheral tolerance by suppressing im-
mune responses against self-antigens and that numeric or func-
tional defects of these cells have been linked to the development of
autoimmunity [2,32,33]. By contrast, high concentrations of Treg
cells were observed in the peripheral blood and in the tumor envi-
ronment of patients affected with a wide range of human cancers,
where they suppress, rather than enhance, immune responses, thus
leading to immune tolerance toward cancer cells and promoting
tumor growth [4,34,35]. Therefore, the depletion of Treg or inter-
latory T cells (Treg) generated in the presence or absence of different
C
C
CD8 Treg 0.5 g/mL 4-HC
p values
39 22 A vs B: p 0.5; A vs C: p  0.5
5 4 A vs B: p  0.8; A vs C: p  0.4
62 27 A vs B: p  0.7; A vs C: p  0.7
latory T cells (Treg) incubated or not with different concentrations of 4-
C
C
CD8 Treg0.5 g/mL 4-HC
p values
40 16 A vs B: p 0.9; A vs C: p  0.5
4 5 A vs B: p  1; A vs C: p 0.8










I. Traverso et al. / Human Immunology 73 (2012) 207-213 211ferencewith their activity could represent an important strategy to
prevent tumor immune escape. In the past, several approaches
have been tried to target regulatory T cells [36]; among them, the
use of cyclophosphamide was reported to be effective in inhibiting
CD4CD25 Treg activity [19]. However, to be considered a valid
reg inhibitor, an agent must target not only CD4CD25 but also
CD8 Treg, which have been observed to be highly represented
within tumor-inﬁltrating lymphocytes [4] and able to strongly in-
hibit antitumor immune responses [37,31]. Here we demonstrate
that 4-HC counteracts both CD8Treg generation and function. This
Fig. 3. Analysis of apoptosis and necrosis induction by 4-hydroperoxycyclophosph
ith interleukin (IL)-2 and IL-10 for 7 days to generate CD8 Treg. 4-HC was added
(white columns). Cultures performed without addition of 4-HC served as controls (g
necrotic (B and D) cells were performed separately at the end of incubation gating fFig. 4. Comparative analysis of 4-hydroperoxycyclophosphamide (4-HC) cytotoxic effect
ells (black columns) and correlation of CD8CD28 Treg mortality with their suppressivﬁnding is important because it supports the use of CY as an inhibi-
tor of the regulatory immune response in combinatorial protocols
in which this drug is associated with other cytotoxic drugs, as well
aswith antitumor immunotherapies. However, the effects on CD8
Treg were mainly evident when the drug was used at a concentra-
tion of 0.5 g/mL, which corresponds to the serum concentration
bserved after intravenous administration of 10 to 20 mg/kg of CY
26]. To the contrary, low or null effects on CD8 Treg were ob-
served at the lower drug concentration (0.1 g/mL), which corre-
sponds to a CY dose of about 2 mg/kg. Although relevant pharma-
(4-HC) during or after CD8 Treg generation. Puriﬁed CD8 T cells were cultured
beginning of incubation (black columns) or on the 6th day of culture for 24 hours
lumns). Immunoﬂuorescence analyses for the evaluation of apoptotic (A and C) or
8 CD28 (A and B) or CD8CD28 (C and D) T cell subpopulations.
   amide






















I. Traverso et al. / Human Immunology 73 (2012) 207-213212cokinetic changes may occur between different species, it is
noteworthy that CY was still reported to be effective in inhibiting
CD4CD25 Treg function when administered in mice at very low
doses (2mg/mouse corresponding to100mg/kg) [20]. Moreover,
a reduction in circulating CD4CD25 Treg numberswas achieved
in humans with an administered dose of CY as low as1.5 mg/kg/
day [22]. These observations likely suggest that the dosage atwhich
4-HC is effective on CD8 Treg (0.5 g/mL) is higher than that
targeting CD4CD25 Treg. Moreover, data relative to the admin-
stration of an intravenous CY dosage determining a drug serum
oncentration close to 0.5 g/mL indicated only a moderate reduc-
tion in CD4non-Treg percentage [38]. This ﬁnding agreeswith our
unpublished observation that 4-HC added at 0.5 g/mL concentra-
ion to unselected PBMC or puriﬁed CD4 T cells does not signiﬁ-
cantly modify the percentage of CD4CD25 T cells (not shown).
ubsequently, new schedules of CY treatment, tailored using tim-
ng and dosages of administration appropriate for each of the 2
ifferent Treg subsets, should be set to efﬁciently target the whole
reg compartment.
Another consideration pertains to the ﬁeld of treatment of au-
oimmunediseases. CYhas been largely adopted as an immunosup-
ressive drug [17] administered at doses providing serum concen-
rations comparable to those demonstrated here to be able to
nhibit CD8 Treg. Indeed, the prolonged use of CY at such doses
ay lead to the progressive eradication of thewhole Treg compart-
ent, thus exposing patients to the risk of becoming resistant to
he drug and/or being affectedwith severe inﬂammatory rebounds.
xperimental evidence of these events has been reported [39,40].
Themechanism bywhich 4-HC exerts its effects on CD8 Treg is
cytotoxity. Indeed, 4-HC inhibition of CD8 Treg function was re-
ported to be directly correlated with the amount of apoptotis/
necrosis–dependent mortality of the target cells. Because periph-
eral blood CD8 Treg do not express the CD28 molecule, it was
ossible todifferentiate aCD8CD28Treg subset fromaCD8CD28
non-Treg subpopulation. Interestingly, when the rates of apoptosis/
necrosis induction was comparatively analyzed in CD8CD28 Treg
and CD8CD28 non-Treg, a signiﬁcantly higher sensitivity to 4-HC
asobserved in the formerof the2T cell subpopulations, reminiscent
f what was already demonstrated when sensitivity to CY of
D4CD25 and CD4CD25 T cell subsets was comparatively ana-
lyzed [20]. Because increased sensitivity to CY seems to be a common
feature of both CD4CD25 and CD8 Treg, it is possible to envisage
the setting of newly articulated protocols for CY administration spe-
ciﬁcally aimed at deleting Treg sparing non-Treg subpopulations (i.e.,
using shortened or pulsed timing of administration). Clinical trials
speciﬁcally designed to investigate this issue could clarifywhether CY
canbe really considered a valid inhibitor of Treg function to beused in
anticancer treatment protocols.
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